Nanobiotix (NASDAQ:NBTX) Shares Gap Up - Should You Buy?

Key Points

• Nanobiotix's stock price surged from a previous close of $10.20 to an opening price of $12.55, indicating strong market interest and activity in the company's shares.
• Institutional investors hold 38.81% of Nanobiotix's stock, with Millennium Management LLC recently acquiring a new stake valued at approximately $39,000.
• The company is focused on developing cancer treatment therapies, particularly its lead product candidate NBTXR3, aimed at various types of tumors.

Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - )'s share price gapped up prior to trading on Thursday . The stock had previously closed at $10.20, but opened at $12.55. Nanobiotix shares last traded at $12.52, with a volume of 219,365 shares changing hands.

Nanobiotix Price Performance

The company's fifty day moving average is $7.71 and its two-hundred day moving average is $5.18.

Institutional Investors Weigh In On Nanobiotix

A hedge fund recently bought a new stake in Nanobiotix stock. Millennium Management LLC purchased a new position in shares of Nanobiotix S.A. Sponsored ADR (NASDAQ:NBTX - Free Report) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 13,452 shares of the company's stock, valued at approximately $39,000. Institutional investors own 38.81% of the company's stock.

Nanobiotix Company Profile

Nanobiotix SA, a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.